Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes

被引：0

作者：

Fenaux, P.

Mufti, G. J.

Hellstrom-Lindberg, E.

机构：

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2009年 / 9卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：395 / 395

页数：1

共 50 条

[31] High-risk myelodysplastic syndromes in hypomethylants failure [J].

Gardin, Claude .

HEMATOLOGIE, 2010, 16 :24-28

[32] Histopathology in the diagnosis of high-risk myelodysplastic syndromes [J].

Kayano, Hidekazu .

JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2018, 58 (02) :51-60

[33] Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes [J].

Musto, Pellegrino ;

Maurillo, Luca ;

Spagnoli, Alessandra ;

Gozzini, Antonella ;

Rivellini, Flavia ;

Lunghi, Monia ;

Villani, Oreste ;

Aloe-Spiriti, Maria Antonietta ;

Venditti, Adriano ;

Santini, Valeria .

CANCER, 2010, 116 (06) :1485-1494

[34] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) [J].

Santini, V. ;

Fenaux, P. ;

Mufti, G. J. ;

Hellstroem-Lindberg, E. ;

List, A. F. ;

Silverman, L. R. ;

Seymour, J. F. ;

Backstrom, J. ;

McKenzie, D. ;

Beach, C. L. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[35] Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation [J].

Garcia-Manero, Guillermo ;

Odenike, Olatoyosi ;

Fleming, Shaun ;

Roboz, Gail J. ;

Jacoby, Meagan ;

Cunningham, Ilona ;

Kreuzer, Karl-Anton ;

Enjeti, Anoop K. ;

Baer, Maria R. ;

Cook, Rachel ;

Jurcic, Joseph ;

Ku, Grace ;

Zhou, Ying ;

Hoffman, David ;

Potluri, Jalaja ;

Garcia, Jacqueline S. .

BLOOD, 2023, 142

[36] Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome [J].

Nishihori, Taiga ;

Perkins, Janelle ;

Mishra, Asmita ;

Komrokji, Rami ;

Kim, Jongphil ;

Kharfan-Dabaja, Mohamed A. ;

Perez, Lia ;

Lancet, Jeffrey ;

Fernandez, Hugo ;

List, Alan ;

Anasetti, Claudio ;

Field, Teresa .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (06) :776-780

[37] Outcome of Low Dose Azacitidine in Patients of Lower Risk Myelodysplastic Syndromes [J].

Ghosh Sr, Kaustav ;

Dolai, Tuphan Kanti ;

Mandal, Prakas Kumar ;

Jena, Rabindra .

BLOOD, 2024, 144 :6697-6698

[38] Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine [J].

Santini, Valeria ;

Amato, Cristina ;

De Pourcq, Sven ;

della Seta, Roberta ;

Caciagli, Barbara ;

Raddi, Marco Gabriele ;

Consagra, Angela ;

Rigodanza, Luca ;

Mattiuz, Giorgio ;

Defina, Marzia ;

Galimberti, Sara ;

Maestrini, Giacomo ;

Sanna, Alessandro .

BLOOD, 2023, 142

[39] EXPERIENCE WITH 5-AZACITIDINE IN PATIENTS DIAGNOSED BY MYELODYSPLASTIC SYNDROMES OF INTERMEDIATE 2/HIGH RISK [J].

Llorente Dunia, De Miguel ;

Lopez Nuria, Golbano ;

Morfa Miguel, Diaz ;

Juanis Jaime, Arbeteta ;

Sanz Dolores, Morales ;

Ramo Alejandro, Vazquez ;

Maqueda Cristina, Fernandez ;

Garcia Helga, Guillen ;

Perez Dolores, Subira ;

Martin Sonia, Herrero ;

Albiz Blanca, Pinedo .

HAEMATOLOGICA, 2016, 101 :341-341

[40] PI-PLCβ-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes [J].

M Y Follo ;

C Finelli ;

C Bosi ;

G Martinelli ;

S Mongiorgi ;

M Baccarani ;

L Manzoli ;

W L Blalock ;

A M Martelli ;

L Cocco .

Leukemia, 2008, 22 :198-200

← 1 2 3 4 5 →